Cover Image

Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling

Dose recommendations for lamivudine or emtricitabine in children with HIV and chronic kidney disease (CKD) are absent or not supported by clinical data. Physiologically based pharmacokinetic (PBPK) models have the potential to facilitate dose selection for these drugs in this population. Existing la...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tom G. Jacobs (Author), Marika A. de Hoop-Sommen (Author), Thomas Nieuwenstein (Author), Joyce E. M. van der Heijden (Author), Saskia N. de Wildt (Author), David M. Burger (Author), Angela Colbers (Author), Jolien J. M. Freriksen (Author)
Format:	Book
Published:	MDPI AG, 2023-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pragmatic physiologically-based pharmacokinetic modeling to support clinical implementation of optimized gentamicin dosing in term neonates and infants: proof-of-concept
by: Marika A. de Hoop-Sommen, et al.
Published: (2023)

Getting the dose right using physiologically-based pharmacokinetic modeling: dexamethasone to prevent post-extubation stridor in children as proof of concept
by: Joyce E. M. van der Heijden, et al.
Published: (2024)

A Comparison between the Efficiency of Vonavir (Tenofovir-Emtricitabine- Efavirenz) and Cobavir (Lamivudine-Zidovudine) with Efavirenz used for HIV Patients in Fasa, Iran
by: Saeideh Honarmand, et al.
Published: (2022)

A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: Piperacillin and Amikacin as Proof of Concept
by: Stan J. F. Hartman, et al.
Published: (2020)

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
by: Eric H. Decloedt, et al.
Published: (2021)

Emtricitabine-induced pure red cell aplasia
by: Nithendra Manickchund, et al.
Published: (2019)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice
by: Canetti D, et al.
Published: (2023)

A case series of emtricitabine-induced pure red cell aplasia
by: Nithendra Manickchund, et al.
Published: (2021)

Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention
by: Meredith R. Clark, et al.
Published: (2014)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
by: Juday T, et al.
Published: (2013)

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
by: Wissam K. Kabbara, et al.
Published: (2015)

Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations
by: Paul Curley, et al.
Published: (2023)

Development of lamivudine containing multiple emulsions stabilized by gum odina
by: Aditya Kumar Jena, et al.
Published: (2018)

Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
by: Torsak Bunupuradah, et al.
Published: (2015)

Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)
by: Anna Gidari, et al.
Published: (2023)

Design and in vivo pharmacokinetic study of a newly developed lamivudine transdermal patch
by: E. Ramadan, et al.
Published: (2018)

A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention
by: Erick Leung, et al.
Published: (2023)

Abacavir/lamivudine combination in the treatment of HIV: a review
by: Geetha Sivasubramanian, et al.
Published: (2010)

The effects of prolonged Lamivudine administration as a sole treatment following the combination therapy of Interferon Alpha and Lamivudine in children for HBeAg (+) chronic hepatitis B
by: Sezin Asik Akman,1 Sabriye Cokceken Okcu,2 Sumer Sutcuoglu.2
Published: (2007)

Development and validation of ultraviolet spectrophotometric methods for lamivudine and zidovudine quantification in dissolution test
by: Enma Perez-Chauca, et al.
Published: (2022)

Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives
by: James AM, et al.
Published: (2013)

Development and validation of analytical method for the estimation of lamivudine in rabbit plasma
by: Akhilesh Vikram Singh, et al.
Published: (2011)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
by: Saye H. Khoo, et al.
Published: (2011)

Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms
by: M. Satya Venkata Sakuntala, et al.
Published: (2021)

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and HBV co-infection
by: Y.-S. Huang, et al.
Published: (2019)

Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trialResearch in context
by: Fujie Zhang, et al.
Published: (2024)

Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B
by: Chao DC, et al.
Published: (2013)

Evaluation of pharmacokinetics underlies the collaborated usage of lamivudine and oxymatrine in beagle dogs
by: Zhenbao Li, et al.
Published: (2016)

Quality by Design Optimization of Cold Sonochemical Synthesis of Zidovudine-Lamivudine Nanosuspensions
by: Bwalya A. Witika, et al.
Published: (2020)

Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
by: Julián Olalla, et al.
Published: (2018)

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
by: Ranzenigo M, et al.
Published: (2022)

Analysis of baseline laboratory characteristics of HIV-positive patients in Bulgaria treated with bictegravir /emtricitabine/ tenofovir anafelamide (early analysis)
by: Dimitar Strashimirov, et al.
Published: (2024)

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
by: Squillace N, et al.
Published: (2018)

The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review
by: Aprilianti S, et al.
Published: (2024)

Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus
by: Hongcan Liu, et al.
Published: (2021)

Equilibrium solubility versus intrinsic dissolution: characterization of lamivudine, stavudine and zidovudine for BCS classification
by: André Bersani Dezani, et al.
Published: (2013)

Impact of tenofovir, lamivudine, and dolutegravir on liver function in HIV-positive individuals in Southern Nigeria
by: Odekunle Bola Odegbemi, et al.
Published: (2024)

Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]
by: Ranzenigo M, et al.
Published: (2022)

Evaluation of urinary excretion of dolutegravir or emtricitabine/tenofovir/elvitegravir/cobicistat antiretroviral-based regimens using plasma and urine trough concentration
by: Jérémy Lourenco, et al.
Published: (2018)

Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 - 2023)
by: Enos Moyo, et al.
Published: (2022)